Medivir AB (MVIRb.F) Release: Positive Results From a Phase Ia Study With MIV-711 for the Treatment of Skeletal Disorders
5/21/2013 9:29:19 AM
More...
|
Medivir AB (MVIRb.F) Release: Primary Efficacy and Safety Findings From Phase III Study of Simeprevir in Treatment-Experienced Patients Demonstrate Sustained Virologic Response
5/21/2013 9:19:22 AM
More...
|
Medivir AB (MVIRb.F): FDA Grants Priority Review to Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C
5/13/2013 11:13:51 AM
More...
|
Medivir AB (MVIRb.F) Release: FDA Grants Priority Review to Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C
5/13/2013 9:50:42 AM
More...
|
Resolutions at the Annual General Meeting in Medivir AB (MVIRb.F) on 6 May 2013
5/6/2013 9:40:23 AM
More...
|
Resolutions at the Annual General Meeting in Medivir AB (MVIRb.F) on 6 May 2013
5/6/2013 9:29:29 AM
More...
|
Medivir AB (MVIRb.F): Webcast Presentation of Simeprevir Phase III Clinical Data
5/3/2013 11:12:36 AM
More...
|
Medivir AB (MVIRb.F): Marketing Authorization Application for Simeprevir to the European Medicines Agency for the Treatment of Patients With Genotype 1 and Genotype 4 Hepatitis C is Now Filed
4/24/2013 11:43:39 AM
More...
|
Medivir AB (MVIRb.F) Release: New Data From Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients Will be Presented at EASL 23-28 April in Amsterdam
4/23/2013 11:49:18 AM
More...
|
Medivir AB (MVIRb.F): Data from Simeprevir in Hepatitis C Patients Will be Presented at EASL During 24-28 April in Amsterdam
4/8/2013 6:49:58 AM
More...
|
|